Publications by authors named "Katy Rutkowski"

Hypertrophic cardiomyopathy (HCM) affects as many as 1 in 200 people in the adult population globally. Patients may present with exertional dyspnea, presyncope or syncope, atrial and ventricular arrhythmias, heart failure, and even sudden cardiac death. Current guideline-based therapy involves medical therapy for treatment of symptoms in milder forms of the disease and surgical or catheter-based septal reduction therapies in obstructive HCM.

View Article and Find Full Text PDF
Article Synopsis
  • Mavacamten is approved for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and aims to improve left ventricular outflow tract gradients and reduce the need for septal reduction therapy (SRT).
  • A study of 150 patients showed significant improvements in New York Heart Association (NYHA) class and reduced LVOT gradients after 12 weeks of mavacamten treatment, with 46% of patients showing at least one class improvement.
  • Although there was a slight decline in left ventricular ejection fraction (LVEF), no patients required SRT or experienced severe heart failure complications during the study period.
View Article and Find Full Text PDF